Podcasts about Cephalalgia

Dans cet épisode, Romain Giop explique en détail les mécanismes en jeu lors des principales douleurs attribuées aux migraines. Il évoque comment traduire la littérature en pratique, quelle place attribuer à la thérapie manuelle, et prodigue quelques conseils utiles aux patients souffrant de migraines, notamment en termes d'activité physique. Extraits sonores Fais pas ci, fais pas ça | Interprété par Jacques Dutronc | Ecrit par Jacques Lanzmann et Anne Segalen | Album : il est cinq heures | 1968 References Watson, D. H. & Drummond, P. D. The Role of the Trigemino Cervical Complex in Chronic Whiplash Associated Headache: A Cross Sectional Study. Headache: J. Head Face Pain 56, 961–975 (2016) Luedtke, K. & May, A. Stratifying migraine patients based on dynamic pain provocation over the upper cervical spine. J. Headache Pain 18, 97 (2017) Burstein, R., Noseda, R. & Borsook, D. Migraine: Multiple Processes, Complex Pathophysiology. J. Neurosci. 35, 6619–6629 (2015) Carvalho, G. F. et al. Physical therapy and migraine: musculoskeletal and balance dysfunctions and their relevance for clinical practice. Braz. J. Phys. Ther. 24, 306–317 (2020) Luedtke, K., Starke, W. & May, A. Musculoskeletal dysfunction in migraine patients. Cephalalgia 38, 865–875 (2017) Soutenez-nous sur Tipeee !

Dando sequência à série "Naruhodo Entrevista" de conversas descontraídas com cientistas brasileiras e brasileiros, chegou a vez da Médica, Mestra e Doutora em Pneumologia, Vice-Reitora da UNIFESP, Lia Rita Bittencourt.Só vem!> OUÇA (82min 09s)*Naruhodo! é o podcast pra quem tem fome de aprender. Ciência, senso comum, curiosidades, desafios e muito mais. Com o leigo curioso, Ken Fujioka, e o cientista PhD, Altay de Souza.Edição: Reginaldo Cursino.http://naruhodo.b9.com.br*Lia Rita Azeredo Bittencourt possui graduação em Medicina pela Universidade Federal do Espírito Santo (1987), concluiu residência em Clínica Médica pelo Hospital Universitário Cassiano Antônio de Moraes -UFES (1988) e residência em Pneumologia pelo Instituto de Assistência Médica ao Servidor Público Estadual - HSPE (1991).Obteve título de especialista em Pneumologia pela Associação Médica Brasileira - AMB (1992), de Mestre em Medicina (Pneumologia) pela Universidade Federal de São Paulo - Unifesp (1995), de Doutor em Medicina (Pneumologia) pela Unifesp (1999) e de área e atuação em Medicina do Sono pela AMB (2012). Foi Chefe da Disciplina de Medicina e Biologia do Sono da Unifesp (2008-2012 e 2017-2018).Foi Vice - Chefe do Departamento de Psicobiologia da Unifesp (2014 - 2015). Fundadora e responsável pela Liga Acadêmica do Sono da Unifesp (2008 - 2018). Foi coordenadora Médica do Instituto do Sono da Associação Fundo de Incentivo à Pesquisa - AFIP (1992-2018). Foi coordenadora do Curso de Capacitação em Medicina do Sono do Instituto do Sono/AFIP (2003 - 2018). Foi Presidente da Associação Brasileira do Sono (2007-2009) e Presidente da Associação Brasileira de Medicina do Sono (2013-2015). Foi membro da Comissão de Prova de Título na Área de Atuação em Medicina do Sono da AMB representando a Sociedade Brasileira de Pneumologia e Tisiologia (2013 - 2017).É orientadora no Curso de Pós-Graduação em Psicobiologia desde 2002 e no Curso de Pós- Graduação em Pneumologia desde 2010 da Unifesp. Atualmente é professora Titular e Livre-docente da Disciplina de Medicina e Biologia do Sono do Departamento de Psicobiologia da Unifesp. Está no cargo de Vice-Reitora da Unifesp (2023-2027).Foi representante Titular dos Professores Associados no Conselho de Graduação da Unifesp (2017 - 2019). Foi Pró-Reitora de Pós-Graduação e Pesquisa da Universidade Federal de São Paulo (2018 - 2023). Foi representante Titular dos Professores Associados do Conselho do Campus São Paulo da Unifesp (2020-2022), representante Suplente dos Professores Associados do Conselho da Congregação da Escola Paulista de Medicina da Unifesp (2019-2021). É bolsista Produtividade Pesquisa 1 B e parecerista do Conselho Nacional de Desenvolvimento Científico e Tecnológico; e em 2024, pelo Chamada CNPq/Decit/SECTICS/MS n 32/2024, faz parte do Comitê Julgador para selecionar projetos de pesquisas pré-clínicas e clínicas estratégicas para o SUS. É também pesquisadora e parecerista da Fundação de Amparo à Pesquisa do Estado de São Paulo.Foi editora da revista Entreteses, editora-associada do periódico Sleep Breathing, Brazilian Journal of Otorhinolaryngology, British Journal of Sports Medicine e do Boletim da Associação Brasileira do Sono, parecerista dos periódicos Sleep, Sleep Medicine, Journal of Clinical Sleep Medicine, Plos One, Cephalalgia, British Joutnal of Sports Medicine,Sleep Science, Journal of Clinical Monitoring and Computing (JCMC),Anais da Academia Brasileira de Ciências, Brazilian Journal of Medical and Biological Research, International Journal of Endocrinology, Journal of Epidemiology and Community Health, Nature and Science of Sleep, Revista Brasileira de Psiquiatria, Revista de Psiquiatria Clínica, Brazilian Journal of Otorhinolaryngology e Jornal Brasileiro de Pneumologia.Tem experiência na área de Medicina, com ênfase em Pneumologia e Medicina do Sono, atuando principalmente nos seguintes temas: epidemiologia, fisiopatologia, diagnóstico, prognóstico e tratamento dos distúrbios respiratórios relacionados ao sono.Lattes: http://lattes.cnpq.br/6882391059348792*APOIE O NARUHODO PELA PLATAFORMA ORELO!Um aviso importantíssimo: o podcast Naruhodo agora está no Orelo: https://bit.ly/naruhodo-no-oreloE é por meio dessa plataforma de apoio aos criadores de conteúdo que você ajuda o Naruhodo a se manter no ar.Você escolhe um valor de contribuição mensal e tem acesso a conteúdos exclusivos, conteúdos antecipados e vantagens especiais.Além disso, você pode ter acesso ao nosso grupo fechado no Telegram, e conversar comigo, com o Altay e com outros apoiadores.E não é só isso: toda vez que você ouvir ou fizer download de um episódio pelo Orelo, vai também estar pingando uns trocadinhos para o nosso projeto.Então, baixe agora mesmo o app Orelo no endereço Orelo.CC ou na sua loja de aplicativos e ajude a fortalecer o conhecimento científico.https://bit.ly/naruhodo-no-orelo

Cluster headaches present through urgent care and it is important to differentiate them correctly.   Check out the paper on which Lisa Kudrow has a credit Messinger HB, Messinger MI, Kudrow L, Kudrow LV. Handedness and headache. Cephalalgia. 1994 Feb;14(1):64-7. doi: 10.1046/j.1468-2982.1994.1401064.x. PMID: 8200028.   Check out the paper mentioned Weaver-Agostoni J. Cluster headache. Am Fam Physician. 2013 Jul 15;88(2):122-8. PMID: 23939643.   This links to the ICHD-3 Cluster Headache page   Check out the BPAC article mentioned   For Bootcamp details - https://rnzcuc.org.nz/urgent-care-bootcamp-2024/    www.rnzcuc.org.nz podcast@rnzcuc.org.nz https://www.facebook.com/rnzcuc https://twitter.com/rnzcuc   Music licensed from www.premiumbeat.com Full Grip by Score Squad   This podcast is intended to assist in ongoing medical education and peer discussion for qualified health professionals.  Please ensure you work within your scope of practice at all times.  For personal medical advice always consult your usual doctor 

MAL DE TETE CRONIQUE COTRE HYPNOSE!decouvre de plus:https://www.claudiosaracino.com/prodotto/no-mal-di-testa-cronico-no-emicrania-metodo-dcs/maldetete #migraine #mauxdeteteComment peut-on éliminer le mal de tête chronique et la migraine grâce à l'hypnose professionnelle : Recherches scientifiques et témoignages de personnages célèbresL'hypnose professionnelle est de plus en plus reconnue comme une méthode efficace pour traiter divers troubles de la santé, y compris les maux de tête chroniques et les migraines. En induisant un état de relaxation profonde et en utilisant des suggestions thérapeutiques, l'hypnose peut aider à réduire la fréquence et l'intensité des migraines. Cet essai explore comment l'hypnose peut être utilisée pour soulager les maux de tête chroniques et les migraines, en s'appuyant sur trois recherches scientifiques et trois témoignages de personnes célèbres.Recherches scientifiques sur l'hypnose et les migrainesAnderson, J. A., & Basker, M. A. (2002) - Une étude publiée dans "Headache: The Journal of Head and Face Pain" a examiné l'efficacité de l'hypnose pour traiter les migraines chez des patients adultes. Les résultats ont montré une réduction significative de la fréquence et de l'intensité des migraines chez les participants ayant suivi des séances d'hypnose par rapport à ceux recevant un traitement standard.Hammond, D. C. (2007) - Dans un article de revue publié dans "American Journal of Clinical Hypnosis", David C. Hammond a passé en revue plusieurs études cliniques sur l'utilisation de l'hypnose pour traiter les migraines et les maux de tête chroniques. Il a conclu que l'hypnose est une méthode efficace et sans effets secondaires majeurs pour la gestion des migraines, soulignant l'importance de techniques de relaxation et de suggestions post-hypnotiques.Melis, P. M., Rooimans, W., Spierings, E. L., & Hoogduin, C. A. (1991) - Une recherche parue dans "Cephalalgia" a étudié l'effet de l'hypnose sur les patients souffrant de maux de tête chroniques. L'étude a révélé que les participants traités par l'hypnose ont montré une diminution significative de la fréquence des maux de tête et une amélioration de la qualité de vie, comparé à un groupe témoin.Témoignages de personnages célèbresPrincess Diana - La princesse de Galles, connue pour son travail humanitaire, a utilisé l'hypnose pour gérer ses migraines et le stress. Selon son thérapeute, l'hypnose a aidé Diana à réduire la fréquence de ses migraines et à mieux gérer les périodes de tension intense.Matt Damon - L'acteur primé a parlé de son expérience positive avec l'hypnose pour arrêter de fumer, mais aussi pour gérer les migraines. Damon a attribué son succès à l'hypnose, notant une diminution notable des épisodes de migraine après avoir commencé les séances.Jackie Kennedy Onassis - L'ancienne Première Dame des États-Unis a utilisé l'hypnose pour traiter ses migraines sévères et récurrentes. L'hypnose lui a fourni un soulagement significatif, améliorant sa capacité à gérer les obligations publiques et personnelles malgré ses douleurs chroniques.ConclusionL'hypnose professionnelle se révèle être une méthode prometteuse pour le traitement des maux de tête chroniques et des migraines. Les recherches scientifiques soulignent son efficacité pour réduire la fréquence et l'intensité des migraines, sans effets secondaires indésirables. Les témoignages de personnalités telles que Princess Diana, Matt Damon et Jackie Kennedy Onassis illustrent également les avantages potentiels de cette approche thérapeutique. En intégrant l'hypnose dans le cadre du traitement des migraines, il est possible d'offrir une alternative ou un complément aux traitements médicaux traditionnels, améliorant ainsi la qualité de vie des personnes souffrant de ces affections débilitantes.

In today's episode I talk about facial pain. 1/3 of non-dental facial pain is idiopathic, meaning without a specific cause. During this episode l discuss the 6 major classifications of facial pain along with the psycho social impacts of facial pain sufferers. I round off the episode by discussing what I'm currently doing in clinic with people struggling with facial pain. Do you suffer from facial pain. If so, what has helped you along the way? Comment below! Episode Resources  *(No authors listed). International Classification of Orofacial Pain, 1st edition (ICOP). Cephalalgia. 2020;40(2):129-221. doi:10.1177/0333102419893823. *Ziegeler C, Beikler T, Gosau M & May A. Idiopathic Facial Pain Syndromes - An Overview and Clinical Implications. Dtsch Arztebl Int. 2021;118(6):81-87. doi:10.3238/arztebl.m2021.0006.  --- Send in a voice message: https://podcasters.spotify.com/pod/show/concast/message

You might encounter an Ice Cream Headache over Christmas.      Check out the International Classification of Headaches - Third Edition) Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013 Jul;33(9):629-808. doi: 10.1177/0333102413485658. PMID: 23771276. https://pubmed.ncbi.nlm.nih.gov/23771276/   Check out the paper mentioned Özyürek H, Koray Bayrak I, Yayici Köken Ö. Ice Cream Headache: Cerebral Blood Flow Evaluation. Turk Arch Pediatr. 2021 Jul 1;56(4):405-406. doi: 10.5152/TurkArchPediatr.2021.20247. PMID: 35005742; PMCID: PMC8655974. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8655974/     www.rnzcuc.org.nz podcast@rnzcuc.org.nz https://www.facebook.com/rnzcuc https://twitter.com/rnzcuc   Music licensed from www.premiumbeat.com Christmas Elves by - Francesco D'Andrea   This podcast is intended to assist in ongoing medical education and peer discussion for qualified health professionals.  Please ensure you work within your scope of practice at all times.  For personal medical advice always consult your usual doctor

Emicrania: è un segnale che manda il cervello o una malattia? A questa domanda da una risposta uno studio pubblicato su Cephalalgia che commentiamo con il prof. Pietro Cortelli, direttore operativo dell’Istituto di Scienze Neurologiche di Bologna e Ordinario di Neurologia all’Università di Bologna, che ha coordinato la ricerca.

In today's podcast, we cover a brand new study by Dev (2023) on using low-dose thyroid hormone in patients with subclinical hypothyroidism (TSH between 4.5-10 mIU/L).  We've seen the connection between slightly elevated TSH and migraine in a few populations, but this is the first clinical trial that attempts to lower headache frequency, intensity and duration with thyroid hormone replacement.  Have a listen to the episode, and be sure to subscribe to The Stacks, our new integrative medicine magazine that's free for subscribers. We'll help you stay up to date, without having to do the research yourself.    References:  1.Bhattacharjee, M. et al. Association of Low Thyroid Hormone with Migraine Headache. Mymensingh Méd. J. : MMJ 30, 43–47 (2021).   2.Dev, P. et al. The effect of low dose thyroid replacement therapy in patients with episodic migraine and subclinical hypothyroidism: A randomised placebo-controlled trial. Cephalalgia 43, 03331024231182684 (2023).   3.Hassan, M. A. E. et al. Potential Association between Subclinical Hypothyroidism and Childhood Migraine. Medicina 58, 1346 (2022).

Côté, P., Yu, H., Shearer, H. M.,  Randhawa, K., Wong, J. J., Mior, S., ... & Lacerte, M. (2019).  Non‐pharmacological management of persistent headaches associated with  neck pain: A clinical practice guideline from the Ontario protocol for  traffic injury management (OPTIMa) collaboration. European journal of pain, 23(6), 1051-1070.Falsiroli Maistrello, L., Rafanelli, M. & Turolla, A. Manual Therapy and Quality of Life in People with Headache: Systematic Review and Meta-analysis of Randomized Controlled Trials. Curr Pain Headache Rep 23, 78 (2019)Luedtke, K., Boissonnault, W.,  Caspersen, N., Castien, R., Chaibi, A., Falla, D., ... & May, A.  (2016). International consensus on the most useful physical examination  tests used by physiotherapists for patients with headache: A Delphi  study. Manual therapy, 23, 17-24.Jull, G., Amiri, M., Bullock-Saxton,  J., Darnell, R., & Lander, C. (2007). Cervical musculoskeletal  impairment in frequent intermittent headache. Part 1: Subjects with  single headaches. Cephalalgia, 27(7), 793-802.Luedtke, K., Starke, W., & May, A. (2018). Musculoskeletal dysfunction in migraine patients. Cephalalgia, 38(5), 865-875.Luedtke, K., Allers, A., Schulte, L. H., & May, A. (2016). Efficacy of interventions used by physiotherapists for patients with headache and migraine—systematic review and meta-analysis. Cephalalgia, 36(5), 474-492.Nilsson, N. (1995). The prevalence of cervicogenic headache in a random population sample of 20–59 year olds. Spine, 20(17), 1884-1888.Rubio-Ochoa, J., Benítez-Martínez, J.,  Lluch, E., Santacruz-Zaragozá, S., Gómez-Contreras, P., & Cook, C.  E. (2016). Physical examination tests for screening and diagnosis of  cervicogenic headache: A systematic review. Manual therapy, 21, 35-40.Satpute, K., Bedekar, N., & Hall,  T. (2020). Headache symptom modification: the relevance of appropriate  manual therapy assessment and management of a patient with features of  migraine and cervicogenic headache–a case report. Journal of Manual & Manipulative Therapy, 28(3), 181-188.

MedLink Neurology Podcast is delighted to feature selected episodes from BrainWaves, courtesy of James E Siegler MD, its originator and host. BrainWaves is an academic audio podcast whose mission is to educate medical providers through clinical cases and topical reviews in neurology, medicine, and the humanities, and episodes originally aired from 2016 to 2021. Originally released: February 1, 2018 Mike Rubenstein, from prior episodes on global health and CSF interpretation, returns to discuss the case of a patient with recurrent headaches. But this time he uses big words. Take a listen. Produced by James E Siegler. Music by Mystery Mammal, Lee Rosevere, Unheard Music Concepts, and Greg Atkinson. Voiceover by Erika Mejia. BrainWaves' podcasts and online content are intended for medical education only and should not be used for routine clinical decision-making. REFERENCES Bigal ME, Lipton RB. The differential diagnosis of chronic daily headaches: an algorithm-based approach. J Headache Pain 2007;8(5):263-72. PMID 17955166 Dodick DW. Clinical practice. Chronic daily headache. N Engl J Med 2006;354(2):158-65. Erratum in: N Engl J Med 2006;354(8):884. PMID 16407511 Goadsby PJ. Trigeminal autonomic cephalalgias. Continuum (Minneap Minn) 2012;18(4):883-95. PMID 22868548 Halker RB, Hastriter EV, Dodick DW. Chronic daily headache: an evidence-based and systematic approach to a challenging problem. Neurology 2011;76(7 Suppl 2):S37-43. PMID 21321350 Pareja JA, Antonaci F, Vincent M. The hemicrania continua diagnosis. Cephalalgia 2001;21(10):940-6. PMID 11843864 Prakash S, Patell R. Paroxysmal hemicrania: an update. Curr Pain Headache Rep 2014;18(4):407. PMID 24523000 Silberstein SD, Lipton RB. Chronic daily headache. Curr Opin Neurol 2000;13(3):277-83. PMID 10871251  We believe that the principles expressed or implied in the podcast remain valid, but certain details may be superseded by evolving knowledge since the episode's original release date.

Season 4 Episode 4   COVID RELATED TE Michelini S et al. Telogen Effluvium in SARS-CoV-2 Infection: histological aspects. J Eur Acad Dermatol Venereol.  2023 Mar 8. M Alharbi et al. Telogen effluvium after COVID-19 vaccination among public in Saudi Arabia. J Family Med Prim Care. 2022 Oct;11(10):6056-6060. Tahmaz A et al. [The Evaluation of Long Coronavirus Disease Symptoms at Ninth Month from a Hospital in Türkiye]. .Mikrobiyol Bul. 2022 Oct;56(4):657-666. Saber M et al. Scalp capillarectasia as a trichoscopic sign of COVID-19-associated telogen effluvium. J Cosmet Dermatol. 2023 Mar 9 Lv S et al. A Case of Acute Telogen Effluvium After SARS-CoV-2 Infection Clin Cosmet Investig Dermatol. 2021; 14: 385–387. Published online 2021 Apr 16.  Willimann B, et al. Hair pain (trichodynia): frequency and relationship to hair loss and patient gender. Dermatology. 2002   HAIR LOSS FROM ANTI-CGRP THERAPIES Ruiz M et al. Alopecia as an emerging adverse event to CGRP monoclonal antibodies: Cases Series, evaluation of FAERS, and literature review. Cephalalgia. 2023 Feb;43(2):3331024221143538.   Sessa M and Andersen M. New insight on the safety of erenumab: an analysis of spontaneous reports of adverse events recorded in the US Food and Drug Administration Adverse Event Reporting System Database. BioDrugs 2021; 35: 215–227   Evers S and Wald S. Effluvium and alopecia associated with monoclonal calcitonin gene-related peptide antibody use. Headache. 2023 Jan;63(1):165-167.   ORAL MINOXIDIL FOR TRACTION ALOPECIA Awad A et al. Low-dose oral minoxidil improves hair density in traction alopecia. J Am Acad Dermatol. 2023 Feb 24;S0190-9622(23)00278-5. Beach RA. Case series of oral minoxidil for androgenetic and traction alopecia: Tolerability & the five C's of oral therapy. Dermatol Ther. 2018 Nov;31(6):e12707. Kim and Craiglow. Treatment of traction alopecia with oral minoxidil. JAAD Case Rep. 2022 Apr 1;23:112-113.   TINEA CAPITIS WORK UP AND TREATMENT IN PEDIATRICS Gold, JA et al. Inadequate diagnostic testing and systemic antifungal prescribing for tinea capitis in an observational cohort study of 3.9 million children, United States. J Am Acad Dermatol. 2023 Feb 15;S0190-9622(23)00189-5.

MedLink Neurology Podcast is delighted to feature selected episodes from BrainWaves, courtesy of James E Siegler MD, its originator and host. BrainWaves is an academic audio podcast whose mission is to educate medical providers through clinical cases and topical reviews in neurology, medicine, and the humanities, and episodes originally aired from 2016 to 2021. Originally released: July 25, 2019 A 50-year-old gentleman presents with severe headaches and speech disturbance. The MRI shows acute strokes and multifocal vascular irregularities. Is it reversible cerebral vasoconstriction syndrome or primary angiitis of the central nervous system? Or is it something else entirely? RCVS and PACNS almost always pose a challenge--even to the most astute neurologist. But, because they are treated entirely differently and their clinical trajectories depend on these treatments, it is worth knowing how experts distinguish the two. This week on the BrainWaves podcast, Dr. Jesse Thon joins Jim Siegler in a discussion about the clinical and radiographic features of these two conditions and shares his experience in managing these patients. Produced by James E Siegler and Jesse Thon. Music courtesy of Nuno Adelaida, Peter Rudenko on the piano, Squire Tuck on the guitar, Swelling, and Uncanny. Sound effects by Mike Koenig and Daniel Simion. BrainWaves' podcasts and online content are intended for medical education only and should not be used for clinical decision-making. Be sure to follow us on Twitter @brainwavesaudio for the latest updates to the podcast. REFERENCES Birnbaum J, Hellmann DB. Primary angiitis of the central nervous system. Arch Neurol 2009;66(6):704-9. PMID 19506130 Miller TR, Shivashankar R, Mossa-Basha M, Gandhi D. Reversible cerebral vasoconstriction syndrome, part 1: epidemiology, pathogenesis, and clinical course. AJNR Am J Neuroradiol 2015;36(8):1392-9. PMID 25593203 Miller TR, Shivashankar R, Mossa-Basha M, Gandhi D. reversible cerebral vasoconstriction syndrome, part 2: Diagnostic work-up, imaging evaluation, and differential diagnosis. AJNR Am J Neuroradiol 2015;36(9):1580-8. PMID 25614476 Rocha EA, Topcuoglu MA, Silva GS, Singhal AB. RCVS2 score and diagnostic approach for reversible cerebral vasoconstriction syndrome. Neurology 2019;92(7):e639-47. PMID 30635475 Singhal AB. Diagnostic challenges in RCVS, PACNS, and other cerebral arteriopathies. Cephalalgia 2011;31(10):1067-70. PMID 21673004 Singhal AB, Topcuoglu MA. Glucocorticoid-associated worsening in reversible cerebral vasoconstriction syndrome. Neurology 2017;88(3):228-36. PMID 27940651 Singhal AB, Topcuoglu MA, Fok JW, et al. Reversible cerebral vasoconstriction syndromes and primary angiitis of the central nervous system: clinical, imaging, and angiographic comparison. Ann Neurol 2016;79(6):882-94. PMID 27043703  We believe that the principles expressed or implied in the podcast remain valid, but certain details may be superseded by evolving knowledge since the episode's original release date. 

MedLink Neurology Podcast is delighted to feature selected episodes from BrainWaves, courtesy of James E Siegler MD, its originator and host. BrainWaves is an academic audio podcast whose mission is to educate medical providers through clinical cases and topical reviews in neurology, medicine, and the humanities, and episodes originally aired from 2016 to 2021. Originally released: June 27, 2019 In episode 142, Jim Siegler is joined by Dr. Deena Kuruvilla (Yale University School of Medicine) to discuss the 5 trigeminal autonomic cephalalgias--what we know about the pathophysiology, the diagnostic criteria, and current and future management strategies. Produced by James E Siegler and Deena Kuruvilla. Music courtesy of Ars Sonor, Axletree, Kevin McLeod, Lee Rosevere, and Steve Combs. Sound effects by Mike Koenig and Daniel Simion. BrainWaves' podcasts and online content are intended for medical education only and should not be used for clinical decision-making. Be sure to follow us on Twitter @BrainWavesaudio for the latest updates to the podcast. REFERENCESAkram H, Miller S, Lagrata S, et al. Ventral tegmental area deep brain stimulation for refractory chronic cluster headache. Neurology 2016;86(18):1676-82. PMID 27029635Goadsby PJ. Trigeminal autonomic cephalalgias. Continuum (Minneap Minn) 2012;18(4):883-95. PMID 22868548Khan S, Olesen A, Ashina M. CGRP, a target for preventive therapy in migraine and cluster headache: systematic review of clinical data. Cephalalgia 2019;39(3):374-89. PMID 29110503Lambru G, Matharu MS. SUNCT, SUNA and trigeminal neuralgia: different disorders or variants of the same disorder? Curr Opin Neurol 2014;27(3):325-31. PMID 24792341McGeeney BE. Cluster headache and other trigeminal autonomic cephalalgias. Semin Neurol 2018;38(6):603-607. PMID 30522134Miller S, Akram H, Lagrata S, Hariz M, Zrinzo L, Matharu M. Ventral tegmental area deep brain stimulation in refractory short-lasting unilateral neuralgiform headache attacks. Brain 2016;139(Pt 10):2631-40. PMID 27524793DISCLOSURES  Dr. Kuruvilla serves as a consultant for Lilly and Amgen pharmaceuticals.We believe that the principles expressed or implied in the podcast remain valid, but certain details may be superseded by evolving knowledge since the episode's original release date.

In a recent study published in Cephalalgia on September 7, 2022, an international group of researchers reported results from a global online survey on perceived barriers to career progression in the headache field. The survey focused on career obstacles in four domains: professional recognition, opportunities in scientific societies, clinical practice, and salary and compensation. Nearly 600 professionals in the global headache field responded to the survey, with gender emerging as the most important barrier in nearly all of the four domains. Country of birth also surfaced as a key barrier. In this MSC podcast, Irene de Boer, first author of the study, along with senior author Gisela Terwindt, sit down with Lincoln Tracy, a research fellow and freelance writer from Melbourne, Australia, to delve deep into the findings from their new work.

In this month's episode of the Psychedelics in Medicine Podcast (PiMPOD), Dr Torsten Passie and Ben Clayden discuss LSD Derivatives, A nearly identical molecule with just a few differences. We discuss multiple derivatives of LSD, including LSA, 2-Bromo-LSD (BOL-148), 1P-LSD and use them in combination to better understand the intricacies of the neural mechanisms of LSD, and how slight changes to a molecules three-dimensional structure can completely alter their effects, through differences in ligand-receptor binding.We then look at a study using a non-hallucinogenic version of LSD, BOL-148 as preventative treatment for cluster headache, discussing its implications, and further research that could be completed relating to LSD derivatives.Dr Passie is a German psychiatrist, professor at Hannover Medical School and is an expert in altered states of consciousness. Torsten has performed clinical and experimental studies numerous psychoactive and psychedelic compounds ranging from nitrous oxide, to MDMA to ketamine.Ben Clayden is the creator and owner of this Podcast. He is a student at the University of York studying Natural Sciences specialising in Neuroscience. He is co-chair for the Drug Science Student Society Network as well as the president of his University's Psychedelics in Medicine Society.Psychedelics, LSD, Hallucinogens Biology, Chemistry, Structural Biology, Neuroscience Cluster Headaches,Useful LinksINSTAGRAM - https://www.instagram.com/psymedpod/LINKTREE - https://linktr.ee/psymedpodRSS - https://rss.com/podcasts/psymedpod/ReferencesKarst M, Halpern JH, Bernateck M, Passie T. The non-hallucinogen 2-bromo-lysergic acid diethylamide as preventative treatment for cluster headache: an open, non-randomized case series. Cephalalgia. 2010 Sep;30(9):1140-4. doi: 10.1177/0333102410363490. Epub 2010 Mar 26. PMID: 20713566.

Assine o Guia TdC - ganhe tempo e atualize-se sem esforço www.tadeclinicagem.com.br/guia Joca apresenta um caso de cefaleia no pronto-socorro para o Kaue e nosso convidado Pedro Fraiman. Discutimos um pouco sobre o que é cefaleia primária e secundária, quando prosseguir investigação, qual exame de imagem pedir e um pouco sobre os diagnósticos diferenciais. Referências: 1. Detsky ME, McDonald DR, Baerlocher MO, Tomlinson GA, McCrory DC, Booth CM. Does This Patient With Headache Have a Migraine or Need Neuroimaging? JAMA. 2006;296(10):1274–1283. doi:10.1001/jama.296.10.1274 2. Robbins MS. Diagnosis and Management of Headache: A Review. JAMA. 2021;325(18):1874–1885. doi:10.1001/jama.2021.1640 3. Chou, Denise E. Secondary headache syndromes. CONTINUUM: Lifelong Learning in Neurology, v. 24, n. 4, p. 1179-1191, 2018. 4. Bigal, Marcelo E.; Bordini, Carlos A.; SPECIALI, J. G. Etiology and distribution of headaches in two Brazilian primary care units. Headache: The Journal of Head and Face Pain, v. 40, n. 3, p. 241-247, 2000. 5. Evans, Randolph W. et al. Neuroimaging for Migraine: The American Headache Society Systematic Review and Evidence‐Based Guideline. Headache: The Journal of Head and Face Pain, v. 60, n. 2, p. 318-336, 2020. 6. Langer-gould, Annette M. et al. The American Academy of Neurology's top five choosing wisely recommendations. Neurology, v. 81, n. 11, p. 1004-1011, 2013. 7. Arnold, Marcel. Headache classification committee of the international headache society (ihs) the international classification of headache disorders. Cephalalgia, v. 38, n. 1, p. 1-211, 2018. 8. Schwedt, Todd J. Thunderclap headache. CONTINUUM: Lifelong Learning in Neurology, v. 21, n. 4, p. 1058-1071, 2015.

Migraines are PAINFUL! And neuroscience speaking - super cool and complicated.  It involves your blood vessels constricting and dilating and your brain going haywire and spreading a wave of neuron depression across your entire cortex. Sound interesting? Come and take a listen to learn a little bit more about what happens in your brain!Please rate, review, and subscribe and if you have any questions, comments, concerns, queries, or complaints, please email me at neuroscienceamateurhour@gmail.com or DM me at NeuroscienceAmateurHour on Instagram.Citations and relevant pictures are below:Headache disorders. www.who.int. https://www.who.int/news-room/fact-sheets/detail/headache-disorders#:~:text=Half%20to%20three%20quarters%20ofMigraine Headaches: Symptoms, Causes, Treatment & Prevention. Cleveland Clinic. Published March 3, 2021. https://my.clevelandclinic.org/health/diseases/5005-migraine-headachesRuthirago D, Julayanont P, Kim J. Translational Correlation. Conn's Translational Neuroscience. Published online 2017:159-165. doi:10.1016/b978-0-12-802381-5.00013-0Mason BN, Russo AF. Vascular Contributions to Migraine: Time to Revisit? Frontiers in Cellular Neuroscience. 2018;12. doi:10.3389/fncel.2018.00233Wikipedia Contributors. Aristides Leão. Wikipedia. Published January 9, 2022. Accessed March 22, 2022. https://en.wikipedia.org/wiki/Aristides_Le%C3%A3oLauritzen M. Pathophysiology of the migraine aura. Brain. 1994;117(1):199-210. doi:10.1093/brain/117.1.199Schain AJ, Melo-Carrillo A, Stratton J, Strassman AM, Burstein R. CSD-Induced Arterial Dilatation and Plasma Protein Extravasation Are Unaffected by Fremanezumab: Implications for CGRP's Role in Migraine with Aura. The Journal of Neuroscience. 2019;39(30):6001-6011. doi:10.1523/jneurosci.0232-19.2019Charles A, Brennan K. Cortical Spreading Depression—New Insights and Persistent Questions. Cephalalgia. 2009;29(10):1115-1124. doi:10.1111/j.1468-2982.2009.01983.xPietrobon D, Striessnig J. Neurobiology of migraine. Nature Reviews Neuroscience. 2003;4(5):386-398. doi:10.1038/nrn1102Eisenstein M. Closing the gender gap in migraine research. Nature. 2020;586(7829):S16-S17. doi:10.1038/d41586-020-02867-4Sutherland HG, Albury CL, Griffiths LR. Advances in genetics of migraine. The Journal of Headache and Pain. 2019;20(1). doi:10.1186/s10194-019-1017-9Support the show (https://www.patreon.com/neuroscienceamateurhour)

Casi el 20% de los pacientes que tuvieron dolor de cabeza durante la enfermedad de la Covid-19, desarrollan después una cefalea crónica frecuente. Así lo revela un estudio de 900 pacientes infectados con el coronavirus durante la primera ola de la pandemia. Los resultados de este estudio fueron publicados en la revista Cephalalgia. Abordar correctamente este síntoma puede evitar que se haga crónico este padecimiento. Son muchos los síntomas poscovid que sufren las personas que desarrollaron la enfermedad de la Covid-19. Entre estos síntomas están los dolores de cabeza o cefaleas. La revista Cephalalgia, publicación oficial de la Sociedad Internacional de Cefaleas (International Headache Society), acaba de publicar los resultados de un estudio realizado por la Sociedad Española de Neurología (SEN). El estudio buscó ver la evolución de 900 pacientes con Covid 19 que padecieron dolor de cabeza durante la enfermedad. Un porcentaje importante de estos pacientes, cerca del 20 % que presentaron dolor de cabeza durante la fase aguda de Covid-19 desarrollan una cefalea crónica diaria. También se observó que cuando el dolor de cabeza poscovid persiste durante un mes, existe un 50 % de probabilidades de que el dolor de cabeza siga presente 9 meses después y dicho dolor de cabeza tiene características similares a la migraña. Se puede acceder al estudio completo aquí. La Sociedad Española de Neurología, a la iniciativa de este estudio, insiste en la importancia de abordar adecuadamente el dolor de cabeza desde el inicio para evitar cronificar este síntoma y que se convierta en una enfermedad. Entrevistado: doctor David García Azorín, neurólogo de la unidad de cefaleas del Hospital Clínico de Valladolid, España, coautor de este estudio y Vocal de la Sociedad Española (SEN). Otros temas relacionados: ¿Cuáles son los síntomas y secuelas neurológicas más comunes con la Covid-19? La Covid 19, además de los pulmones, puede impactar al sistema cardiovascular y neurológico El cerebro femenino: más empático y conectado Escuche aquí nuestra entrevista con el neurólogo David García Azorín:

In this episode, I review an article on alternatives to Ibuprofen. This episode is sponsored by McNeese Construction. You can also read this episode on our blog at https://yopistudio.blogspot.com/2022/03/natural-alternatives-for-ibuprofen.html To keep this podcast going please feel free to donate at www.paypal.me/yopistudio If you would like to read more on this topic or any other previous topics, you can do so by checking out our blog at https://yopistudio.blogspot.com/ Feel free to see what we are up to by following us at:  https://twitter.com/Dauricee https://parler.com/profile/Daurice/ https://www.facebook.com/yopistudio/ https://www.facebook.com/LouisianaEntertainmentAssociation/ To listen to the podcast, watch creative videos and skits go to https://www.youtube.com/channel/UCvn6tns6wKUwz9xZw11_vAQ/videos Interested in projects Daurice has worked on in the movie industry you can check it out at www.IMDb.com under Daurice Cummings. Please add us to your RSS Feed, & iTunes, iHeart, Spotify, Stitcher, Google Pod, Sound Cloud, and our favorite Podbean! For comments or questions, you can reach us at yopi@post.com To read more about today's topic check out the references below. References: https://www.forbes.com/2004/12/13/cx_mh_1213faceoftheyear.html?sh=7432b7776d57 https://www.reuters.com/article/us-painkillers-risks/high-doses-of-common-painkillers-increase-heart-attack-risks-idUSBRE94S1FV20130529?feedType=RSS&feedName=healthNews https://www.greenmedinfo.com/blog/ibuprofen-kills-more-pain-so-what-alternatives https://www.greenmedinfo.com/blog/ibuprofen-can-stop-your-heart-31-increase-cardiac-arrest-risk https://www.greenmedinfo.com/blog/ibuprofen-deadly-vioxx https://www.greenmedinfo.com/toxic-ingredient/ibuprofen https://www.greenmedinfo.com/substance/arnica https://www.greenmedinfo.com/article/topical-treatment-arnica-effective-ibuprofen-hand-osteoarthritis https://www.greenmedinfo.com/substance/ginger https://www.greenmedinfo.com/article/ginger-effective-mefenamic-acid-and-ibuprofen-relieving-pain-women-primary-dys https://www.greenmedinfo.com/substance/turmeric https://www.greenmedinfo.com/article/efficacy-and-safety-curcuma-domestica-extracts-compared-ibuprofen-patients-kne https://www.greenmedinfo.com/substance/thyme https://www.greenmedinfo.com/article/thymus-vulgaris-least-effective-ibuprofen-reducing-severity-pain-and-spasm-pri https://www.greenmedinfo.com/substance/omega-3-fatty-acids https://www.greenmedinfo.com/article/omega-3-fatty-acids-are-effective-alternative-ibuprofen-reducing-arthritic-pai https://www.greenmedinfo.com/substance/cinnamon https://www.greenmedinfo.com/blog/cinnamon-beats-ibuprofen-pain-study-reveals-2 https://www.greenmedinfo.com/pharmacological-action/anti-inflammatory-agents https://www.greenmedinfo.com/pharmacological-action/analgesics https://www.greenmedinfo.com/blog/powerful-aspirin-alternative-grows-trees-1 https://www.greenmedinfo.com/toxic-ingredient/non-steroidal-anti-inflammatory-drugs-nsaids Fitzgerald, G.A. (2001). The coxibs, selective inhibitors of cyclooxygenase-2. New England Journal of Medicine, 345, 433-442. Fitzgerald, G.A. (2004). Coxibs and cardiovascular disease. The New England Journal of Medicine, 351(17), 1709-1711.  Coxib and traditional NSAID Trialists' (CNT) Collaboration et al. (2013). Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet, 382(9849), 769-779. doi: 10.1016/S0140-6736(13)60900-9 Mukherjee, D., Nissen, S.E., & Topol, E.J. (2001). Risk of Cardiovascular Events Associated With Selective COX-2 Inhibitors. Journal of the American Medical Association, 286(8), 954-959. doi:10.1001/jama.286.8.954doi:10.1001/jama.286.8.954 Singh, D. (2004). Merck withdraws arthritis drug worldwide. The British Medical Journal, 329. doi: link.  Berenson et al. (2004). Despite Warnings, Drug Giant Took Long Path to Vioxx Recall. The New York Times. Retrieved from here.  Tanne, J.H. (2008). Merck used ghostwriters and selective data in Vioxx publications, JAMA says. British Medical Journal, 336(849). doi: link.  Steenhuysen, J. (2009). Vioxx risks could have been detected earlier: study. Reuters. Retrieved from here. Willson, D. (2011). Merck to Pay $950 Million Over Vioxx. The New York Times. Retrieved from here. The Associated Press. (2010). Supreme Court Allows Investors to Sue Merck Over Vioxx. The New York Times. Retrieved from here.  ConsumerAffairs. (2004). The Food and Drug Administration (FDA) estimates that Vioxx may have contributed to 27,785 heart attacks. Retrieved from here.  Kearney et al. (2006). Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drug increase the risk of atherothrombosis? Meta-analysis of randomised trials. British Medical Journal, 332, 1302-1308.  McGettigan, P., & Henry, D. (2011). Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Medicine, 8, e1001098.  Trelle et al. (2011). Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. British Medical Journal, 342, c7086.  Sostres, C., Gargallo, C.J., & Lanas, A. (2013). Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage. Arthritis Research Therapies, 15(Suppl 3), S3.   Marlicz et al. (2014). Nonsteroidal anti-inflammatory drugs, proton pump inhibitors, and gastrointestinal injury: contrasting interactions in the stomach and small intestine. Mayo Clinic Proceedings, 89(12), 1699-1709.  Maiden et al. (2005). A quantitative analysis of NSAID-induced small bowel pathology by capsule endoscopy. Gastroenterology, 128(5), 1172-1178. Goldstein et al. (2005). Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole and placebo. Clinical Gastroenterology and Hepatology, 3(2), 133-141.  Shiotani et al. (2010). Randomized, double-blind pilot study of gnarly geranylacetone versus placebo in patients taking low dose enteric-coated aspirin: low-dose aspirin-induced small bowel damage. Scandinavian Journal of Gastroenterology, 45(3), 292-298.  Caunedo-Alvarez et al. (2010). Macroscopic small bowel mucosal injury caused by chronic non steroidal anti-inflammatory drugs (NSAIDs) use as assessed by capsule endoscopy. Rev Esp Enferm Dig, 102(2), 80-85. Kent, T.H., Cardelli, R.M., & Stamler, F.W. (1969). Small intestinal ulcers and intestinal flora in rats given indomethacin. American Journal of Pathology, 54(2), 237-249. Uejima et al. (1996). Role of intestinal bacteria in ileal ulcer formation in rats treated with a non steroidal anti-inflammatory drug. Microbiology and Immunology, 40(8), 553-560.  Watanbe et al. (2008). Non-steroidal anti-inflammatory drug-induced intestinal damage is Toll like 4 receptor dependent. Gut, 57(2), 181-187. Fasano, A. (2012). Leaky gut and autoimmune disease. Clinical Reviews in Allergy and Immunology, 42(1), 71-78.  Lanza, F.L., Chan, F.K., & Quigley, E.M. (2009). Practice parameters committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. American Journal of Gastroenterology, 104(2), 728-238.  Bhatt et al. (2008). ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of anti platelet therapy and NSAID use: A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation, 118(18), 1894-1909.  American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis and Rheumatology, 46(2), 328-346.  Wallace et al. (2011). Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology, 141(4), 1314-1322.   Endo et al. (2011). Efficacy of Lactobacillus casei treatment on small bowel injury in chronic low-dose aspirin users: a pilot randomized controlled study. Journal of Gastroenterology, 46(7), 894-905.  Bhala et al. (2013). Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. The Lancet, 382(9894), 769-779.  Montenegro et al. (2014). Non steroidal anti-inflammatory drug induced damage on lower gastro-intestinal tract: is there an involvement of microbiota? Current Drug Safety, 9(3), 196-204. Ozgoli, G., Goli, M., & Moattar, F. (2009). Comparison of effects of ginger, mefenamic acid, and ibuprofen on pain in women with primary dysmenorrhea. Journal of Alternative and Complementary Medicine, 15(2), 129-132. doi: 10.1089/acm.2008.0311. Salmalian et al. (2014). Comparative effect of thymus vulgaris and ibuprofen on primary dysmenorrhea: A triple-blind clinical study. Caspian Journal of Internal Medicine, 5(2), 82-88.  Levy et al. (2009). Flavocoxid is as effective as naproxen for managing the signs and symptoms of osteoarthritis of the knee in humans: a short-term randomized, double-blind pilot study. Nutrition Research, 29(5), 298-304. doi: 10.1016/j.nutres.2009.04.003. Conrozier et al. (2014). A Complex of Three Natural Anti-inflammatory Agents Provides Relief of Osteoarthritis Pain. Alternative Therapies in Health and Medicine, 20(Suppl 1), 32-37.  Chiu et al. (2016). Effects of Intravenous and Oral Magnesium on Reducing Migraine: A Meta-analysis of Randomized Controlled Trials. Pain Physician, 19(1), E97-E112. Diener et al. (2005). Efficacy and safety of 6.25 mg tid feverfew CO2‐extract (MIG‐99) in migraine prevention—a randomized, double‐blind, multicentre, Placebo‐controlled study. Cephalalgia, 25(11), 1031–1041. Lipton et al. (2004). Petasites hybridus root (butterbur) is an effective preventive treatment for migraine. Neurology, 63(12), 2240-2244.  Shara, M., & Stohs, S.J. (2015). Efficacy and Safety of White Willow Bark (Salix alba) Extracts. Physiotherapy Research, 29(8), 1112-1116. doi: 10.1002/ptr.5377. Vlachojannis, J.E., Cameron, M., & Chrubasik, S. (2009). A systematic review on the effectiveness of willow bark for musculoskeletal pain. Phytotherapy Research, 23(7), 897-900. doi: 10.1002/ptr.2747. Wesolowska et al. (2006). Analgesic and sedative activities of lactucin and some lactucin-like guaianolides in mice. Journal of Ethnopharmacology, 107, 254-258. Gupta, S.K., & Ansari, S.H. (2005). Review on phytochemical and pharmacological aspects of Cichorium intybus L. Asian Journal of Chemistry, 17, 33-36. Tall et al. (2004). Tart cherry anthocyanins suppress inflammation-induced pain behavior in rat. Brain and Behavior Research, 153(1), 181-188. Seeram et al. (2001). Cyclooxygenase inhibitory and antioxidant cyanidin glycosides in cherries and berries. Phytomedicine, 8(5), 362-369. Kuehl et al. (2010). Efficacy of tart cherry juice in reducing muscle pain during running: a randomized controlled trial. Journal of International Society of Sports Nutrition, 7, 17. doi: 10.1186/1550-2783-7-17. Illich, I. (1974). Medical Nemesis: The Expropriation of Health. New York: Pantheon Books. Capone et al. (2004). Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects.          

Tres millones de de personas en España tienen una enfermedad rara y se estima que existen más de 7.000 patologías de este tipo. La Federación Española de Enfermedades Raras asegura que en el 47 por ciento de los casos hay dificultades en el tratamiento y otros ni siquiera tienen un diagnóstico. El Instituto de Salud Carlos III atiene a varios centenares de pacientes. Más de 300 millones de personas en el mundo conviven con las enfermedades poco frecuentes, muchas de las cuales no tienen ningún tratamiento y sólo el 5% de ellas cuenta con medicamentos. El Instituto de Investigación de Enfermedades Raras, dependiente del Carlos III, dispone de un programa de investigación especializado en los casos que no han podido ser diagnosticados en el sistema sanitario. Eva Bermejo, directora del centro, explica que son pacientes que llegan después de haber pasado por distintos servicios médicos de diferentes hospitales y, a veces, de varios países. Es lo que llaman la odisea diagnóstica. El centro atiende a varios centenares de pacientes, realizando diferentes estudios, especialmente genéticos, y tienen unas 200 solicitudes. Eva Bermejo estuvo la semana pasada en Murcia para impartir una conferencia organizada por la Fundación de Estudios Médicos de Molina de Segura.Por otra parte, casi el 20% de los pacientes que sufre dolor de cabeza durante la COVID-19 desarrolla una cefalea crónica diaria después. Las características son similares a las de la migraña. Según un estudio de la Sociedad Española de Neurología, cuando el dolor persiste durante un mes después de haber pasado la enfermedad, existe un 50% de probabilidades de que siga presente, al menos, 9 meses. De todos los pacientes, cerca de la mitad no tenía antecedentes previos de cefalea. Además, los que la padecen después de 9 meses son sobre todo personas mayores, más frecuentemente mujeres. Uno de los autores del estudio y vocal de la Sociedad, el neurólogo yeclano David García Azorín, cree que se debe tratar a los pacientes postcovid que tienen síntomas durante un mes. De este modo, pretenden evitar cronificar los síntomas y que se conviertan en una enfermedad. El neurólogo explica que están trabajando sobre un posible tratamiento pero la dificultad es que se trata de una enfermedad nueva, aunque los síntomas sean similares a una cefalea tensional o una migraña. De momento los adaptan a los tratamientos existentes. Los resultados del estudio han sido publicados en la revista Cephalalgia, la publicación oficial de la Sociedad Internacional de Cefaleas.También les contamos que alergólogos de hospitales españoles, entre los que se encuentra un equipo de la Región, han hallado un nuevo alérgeno del polen de melocotonero, que provoca síntomas respiratorios similares a los del polen de olivo. Los investigadores han comparado a 500 pacientes del hospital Infanta Leonor, de Madrid, que tienen alergia al polen, con 3.000 residentes en el valle de Ricote, sobre todo de Blanca, por su exposición al polen de melocotonero. Laura Victorio, alergóloga del Hospital Morales Meseguer, explica que el alérgeno, del que no se tenía constancia hasta el momento, provoca síntomas respiratorios similares a los del polen de olivo tanto en niños como en adultos. La investigación continúa, según explica Laura Victorio. El siguiente paso es comprobar que el polen se expande a otros municipios, como sucede con el del olivo. El estudio ha sido coordinado por el Hospital Infanta Leonor, de Madrid, y financiado a través de un proyecto del Instituto de Salud Carlos III. Por otra parte, explica que se prevé un aumento de los síntomas de alergias y su tratamiento este año por el menor uso de mascarillas. También influye la sequía y el adelanto de la floración.Además, el alumnado de Jumilla ha conocido de primera mano las investigaciones que el CSIC realiza en materia de control de plagas agrícolas, en una charla dentro del proyecto Ciudad Ciencia al que Jumilla se sumó en 2015 y que explica nuestra compañera Patricia Jiménez; y Antonio, Roberto, Juan y José, alumnos del colegio Nuestra Señora de Fátima de Molina.

David W. Dodick, MD, FRCP (C), FACP is a Professor of Neurology at the Mayo Clinic College of Medicine, and a consultant in neurology at the Mayo Clinic in Scottsdale, Arizona. At Mayo Clinic in Arizona, Dodick serves as the Director of the Headache Program and the Sports Neurology & Concussion Program.   Dr. Dodick is board certified by the Royal College of Physicians and Surgeons of Canada, and the American Board of Psychiatry and Neurology (ABPN). He also holds United Council for Neurologic Subspecialties certification in headache medicine and ABPN certification in vascular neurology. Dr. Dodick has authored more than 350 peer-reviewed publications and authored/edited 10 books. He is the Chair of the Sports Concussion Conference Workgroup and the AAN Annual Sports Concussion Conference of the American Academy of Neurology; and a member of the AAN's Annual Meeting Committee. He is a member of the scientific committee of the International Migraine Trust. He is Chair of the International Headache Academy. He is on the editorial board of several journals including Lancet Neurology, Journal of Neurology, Neurosurgery and Psychiatry, Postgraduate Medicine, Headache, and Cephalalgia.   Dr. Dodcik is the former President of the International Headache Society, former President of the American Headache Society, Chair of the American Migraine Foundation, Director of the US Academic Headache Consortium, and former Editor-in-Chief of Cephalalgia.   —   In today's podcast with Dr. Dodick we'll cover: 1. Dr. Dodick's professional journey 2. What is a concussion? 3. What is the future of concussion testing? 4. What is Synaquell? 5. The future of contact athletics. Have questions about this episode? Fill out the form below and we will connect with you directly! https://www.hawkindynamics.com/hawkinpodcast   Hawkin Dynamics is an industry leader in force plates, education, and support. Check out www.HawkinDynamics.com to learn more, or request a hassle-free quote to see what the HD System costs, here.

Host: Jerome Lisk, MD Guest: Merle Diamond, MD With migraine as a major global health problem that affects over 10% of the population, approximately 1 billion globally, and about 12% in the US, now more than ever it's vital that healthcare professionals have a deep understanding of the role of the calcitonin gene-related peptide (CGRP) and its receptor in migraine pathophysiology1,2,3. That's why Dr. Merle Lea Diamond joins Dr. Jerome Lisk to review that and more. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Lancet. 2018;392:1789-1858. Lipton RB, et al. Neurology. 2007;68:343-349. Lassen LH, et al. Cephalalgia. 2002;22:54-61. USA-334-84583

In this month's episode, we review everything there is to know about vestibular migraine! Follow us on Instagram: @adoseofdizzypodcast References: Lempert, T., Olesen, J., Furman, J., Waterston, J., Seemungal, B., Carey, J., ... & Newman-Toker, D. (2012). Vestibular migraine: diagnostic criteria. Journal of Vestibular Research, 22(4), 167-172. Huang, T. C., Wang, S. J., & Kheradmand, A. (2020). Vestibular migraine: an update on current understanding and future directions. Cephalalgia, 40(1), 107-121.

A look at the top medical headlines for the week of October 11, 2020 including: A group of black physicians has created a task force to vet government decisions about COVID-19 including treatments and a possible vaccine. Then, a study showing that many youths don’t understand just how strict social distancing has to be in order to work, or that restrictions are more than a short-term requirement. And finally, migraine headaches are the third most prevalent illness in the world… but exposure to the right kind of green light can make sufferers feel much better.

Webster defines ‘idiopathic’ as “arising spontaneously or from an obscure or unknown cause”. By definition, this means idiopathic intracranial hypertension (IIH) has no proximate cause. But that’s not exactly true. This week on the podcast, we explore the recent evidence behind the theory that transverse sinus stenosis may contribute to this condition. Disclaimer: No chicken or eggs were harmed in the making of this episode. Produced by James E. Siegler. Music courtesy of Squire Tuck, Swelling, Three Chain Links, and Unheard Music Concepts. The opening theme was composed by Jimothy Dalton. Sound effects by Mike Koenig and Daniel Simion. Unless otherwise mentioned in the podcast, no competing financial interests exist in the content of this episode. BrainWaves' podcasts and online content are intended for medical education only and should not be used for clinical decision making. Be sure to follow us on Twitter @brainwavesaudio for the latest updates to the podcast. REFERENCES Martins AN. Resistance to drainage of cerebrospinal fluid: clinical measurement and significance. Journal of neurology, neurosurgery, and psychiatry. 1973;36:313-8. Gjerris F, Soelberg Sorensen P, Vorstrup S and Paulson OB. Intracranial pressure, conductance to cerebrospinal fluid outflow, and cerebral blood flow in patients with benign intracranial hypertension (pseudotumor cerebri). Annals of neurology. 1985;17:158-62. Orefice G, Celentano L, Scaglione M, Davoli M and Striano S. Radioisotopic cisternography in benign intracranial hypertension of young obese women. A seven-case study and pathogenetic suggestions. Acta Neurol (Napoli). 1992;14:39-50. Karahalios DG, Rekate HL, Khayata MH and Apostolides PJ. Elevated intracranial venous pressure as a universal mechanism in pseudotumor cerebri of varying etiologies. Neurology. 1996;46:198-202. King JO, Mitchell PJ, Thomson KR and Tress BM. Manometry combined with cervical puncture in idiopathic intracranial hypertension. Neurology. 2002;58:26-30. Farb RI, Vanek I, Scott JN, Mikulis DJ, Willinsky RA, Tomlinson G and terBrugge KG. Idiopathic intracranial hypertension: the prevalence and morphology of sinovenous stenosis. Neurology. 2003;60:1418-24. Rohr A, Dorner L, Stingele R, Buhl R, Alfke K and Jansen O. Reversibility of venous sinus obstruction in idiopathic intracranial hypertension. AJNR American journal of neuroradiology. 2007;28:656-9. Sinclair AJ, Kuruvath S, Sen D, Nightingale PG, Burdon MA and Flint G. Is cerebrospinal fluid shunting in idiopathic intracranial hypertension worthwhile? A 10-year review. Cephalalgia. 2011;31:1627-33. Riggeal BD, Bruce BB, Saindane AM, Ridha MA, Kelly LP, Newman NJ and Biousse V. Clinical course of idiopathic intracranial hypertension with transverse sinus stenosis. Neurology. 2013;80:289-95. Satti SR, Leishangthem L and Chaudry MI. Meta-Analysis of CSF Diversion Procedures and Dural Venous Sinus Stenting in the Setting of Medically Refractory Idiopathic Intracranial Hypertension. AJNR American journal of neuroradiology. 2015;36:1899-904. Dinkin MJ and Patsalides A. Venous Sinus Stenting in Idiopathic Intracranial Hypertension: Results of a Prospective Trial. J Neuroophthalmol. 2017;37:113-121. Mohammaden MH, Husain MR, Brunozzi D, Hussein AE, Atwal G, Charbel FT and Alaraj A. Role of Resistivity Index Analysis in the Prediction of Hemodynamically Significant Venous Sinus Stenosis in Patient With Idiopathic Intracranial Hypertension. Neurosurgery. 2020;86:631-636.

Hoje vou começar uma série explicando como me mantenho atualizada. Gravei este podcast em uma live no Instagram (me siga: @dtmdororofacial). Mas antes de começar é preciso falar sobre algumas coisas. Eu acho que precisamos sempre trabalhar dentro da melhor evidência possível e fazer uma ponte entre o que o conhecimento científico revela e como aplicar isso no consultório. Adoro andar nesta ponte. Entender um pouquinho de metodologia científica ajuda muito. Mas se você não teve esta possibilidade, não quer dizer que não possa ir atrás! Eu mesma comprei um livro tempos atrás para entender melhor. O nome do livro era inclusive: Como ler um artigo científico.  Aqui vai o link para versão: https://amzn.to/2MK8UCO ou na versão para Kindle: https://amzn.to/2MHH4qI Para me manter informada criei uma série de estratégias. E a primeira, que falarei agora é buscar ler trabalhos publicados em revistas com fator de impacto alto. Talvez até lendo revisões sobre determinado assunto publicados nestas revistas. Eu entro nas revistas e cadastro meu email na newsletter deles. Com isso, assim que os artigos que foram aceitos nestas revistas, eu recebo um email com o título deles, e abro aqueles que me interessam. Baixo aqueles em que no resumo achei algo que quero ler mais!  Para quem está curioso em saber quais são as revistas com maior impacto na dor orofacial, ou seja, as que eu consulto, vou agora colocar aqui abaixo a minha listinha (organizada por fator de impacto e abrangendo dor orofacial, DTM, cefaleia, sono e bruxismo): 1. Lancet Neurology - https://www.thelancet.com/journals/laneur/home
 2. Neurology - https://n.neurology.org
 3. Pain - https://journals.lww.com/pain/pages/default.aspx
 4. Journal of Pain - https://www.jpain.org
 5. Journal of Dental Research - https://journals.sagepub.com/home/jdr
 6. Sleep - https://academic.oup.com/sleep
 7. Cephalalgia - https://journals.sagepub.com/home/cep 
 8. European Journal of Pain - https://onlinelibrary.wiley.com/journal/15322149 
 9. Journal of Headache and Pain - https://thejournalofheadacheandpain.biomedcentral.com 
 10. Headache: https://headachejournal.onlinelibrary.wiley.com 
 11. Sleep Medicine - https://www.journals.elsevier.com/sleep-medicine
 12. Clinical Journal of Pain: https://journals.lww.com/clinicalpain/pages/default.aspx 
 13. Current Pain and Headache Reports: https://link.springer.com/journal/11916 
 14. Pain Medicine: https://academic.oup.com/painmedicine 
 15. Journal of Oral Rehabilitation - https://onlinelibrary.wiley.com/journal/13652842
 16. Brazilian Oral Research - http://www.scielo.br/bor
 17. Oral Surgery Oral Medicine Oral Pathology Oral Radiology - https://www.oooojournal.net
 18. Archives of Oral Biology - https://www.journals.elsevier.com/archives-of-oral-biology
 19. Journal of Applied Oral Science - http://www.scielo.br/scielo.php?script=sci_serial&pid=1678-7757&lng=en&nrm=iso
 20. Journal of Oral & Facial Pain and Headache:  http://www.quintpub.com/journals/ofph/full_txt_pdf_alert.php?article_id=18895
 Pessoal, fazendo a lista vi que deixei um monte de revistas que chegam no meu email de fora, mas acho que a lista já está bem extensa.   Ah! Não tem dica da semana neste episódio! Afinal o próprio tema é uma dica né? Até a próxima! Veja o texto completo desta descrição em www.julianadentista.com

A 50-year-old gentleman presents with severe headaches and speech disturbance. The MRI shows acute strokes and multifocal vascular irregularities. Is it reversible cerebral vasoconstriction syndrome or primary angiitis of the central nervous system? Or is it something else entirely? RCVS and PACNS almost always pose a challenge--even to the most astute neurologist. But, because they are treated entirely differently and their clinical trajectories depend on these treatments, it is worth knowing how experts distinguish the two. This week on the BrainWaves podcast, Dr. Jesse Thon joins Jim Siegler in a discussion about the clinical and radiographic features of these two conditions, and shares his experience in managing these patients. Produced by James E. Siegler and Jesse Thon. Music courtesy of Nuno Adelaida, Peter Rudenko on the piano, Squire Tuck on the guitar, Swelling, and Uncanny. Sound effects by Mike Koenig and Daniel Simion. BrainWaves' podcasts and online content are intended for medical education only and should not be used for clinical decision making. Be sure to follow us on Twitter @brainwavesaudio for the latest updates to the podcast. REFERENCES Singhal AB. Diagnostic challenges in RCVS, PACNS, and other cerebral arteriopathies. Cephalalgia. 2011;31:1067-70. Miller TR, Shivashankar R, Mossa-Basha M and Gandhi D. Reversible Cerebral Vasoconstriction Syndrome, Part 2: Diagnostic Work-Up, Imaging Evaluation, and Differential Diagnosis. AJNR American journal of neuroradiology. 2015;36:1580-8. Miller TR, Shivashankar R, Mossa-Basha M and Gandhi D. Reversible Cerebral Vasoconstriction Syndrome, Part 1: Epidemiology, Pathogenesis, and Clinical Course. AJNR American journal of neuroradiology. 2015;36:1392-9. Singhal AB, Topcuoglu MA, Fok JW, Kursun O, Nogueira RG, Frosch MP and Caviness VS, Jr. Reversible cerebral vasoconstriction syndromes and primary angiitis of the central nervous system: clinical, imaging, and angiographic comparison. Annals of neurology. 2016;79:882-94. Singhal AB and Topcuoglu MA. Glucocorticoid-associated worsening in reversible cerebral vasoconstriction syndrome. Neurology. 2017;88:228-236. Rocha EA, Topcuoglu MA, Silva GS and Singhal AB. RCVS2 score and diagnostic approach for reversible cerebral vasoconstriction syndrome. Neurology. 2019;92:e639-e647. Birnbaum J and Hellmann DB. Primary angiitis of the central nervous system. Archives of neurology. 2009;66:704-9.

In episode 142, Jim Siegler is joined by Dr. Deena Kuruvilla (Yale University School of Medicine) to discuss the 5 trigeminal autonomic cephalalgias--what we know about the pathophysiology, the diagnostic criteria, and current and future management strategies. Produced by James E. Siegler and Deena Kuruvilla. Music courtesy of Ars Sonor, Axletree, Kevin McLeod, Lee Rosevere, and Steve Combs. Sound effects by Mike Koenig and Daniel Simion. BrainWaves' podcasts and online content are intended for medical education only and should not be used for clinical decision making. Be sure to follow us on Twitter @brainwavesaudio for the latest updates to the podcast. REFERENCES Goadsby PJ. Trigeminal autonomic cephalalgias. Continuum (Minneap Minn). 2012;18:883-895 Lambru G, Matharu MS. Sunct, suna and trigeminal neuralgia: Different disorders or variants of the same disorder? Curr Opin Neurol. 2014;27:325-331 Akram H, Miller S, Lagrata S, Hyam J, Jahanshahi M, Hariz M, et al. Ventral tegmental area deep brain stimulation for refractory chronic cluster headache. Neurology. 2016;86:1676-1682 Miller S, Akram H, Lagrata S, Hariz M, Zrinzo L, Matharu M. Ventral tegmental area deep brain stimulation in refractory short-lasting unilateral neuralgiform headache attacks. Brain. 2016;139:2631-2640 McGeeney BE. Cluster headache and other trigeminal autonomic cephalalgias. Semin Neurol. 2018;38:603-607 Khan S, Olesen A, Ashina M. Cgrp, a target for preventive therapy in migraine and cluster headache: Systematic review of clinical data. Cephalalgia. 2019;39:374-389 DISCLOSURES Dr. Kuruvilla serves as a consultant for Lilly and Amgen pharmaceuticals.

Author: Don Stader, MD Educational Pearls: Cyclic vomiting syndrome (CVS) is different than cannabis hyperemesis syndrome (CHS). It is important to differentiate the two. CHS is thought to be caused by activation of THC receptors in the gut CVS is associated with migraines and therefore responds to similar medications Olanzapine (Zyprexa) is an alternative to haloperidol (Haldol) Amitriptyline, as well as anti-epileptics can be used to prevent CVS Opioids worsen CVS References Lapoint J, Meyer S, Yu CK, Koenig KL, Lev R, Thihalolipavan S, Staats K, Kahn CA.Cannabinoid Hyperemesis Syndrome: Public Health Implications and a Novel Model Treatment Guideline. West J Emerg Med. 2018 Mar;19(2):380-386. doi: 10.5811/westjem.2017.11.36368. Epub 2017 Nov 8. PubMed PMID: 29560069; PubMed Central PMCID: PMC5851514. Boles RG, Lovett-Barr MR, Preston A, Li BU, Adams K. Treatment of cyclic vomiting syndrome with co-enzyme Q10 and amitriptyline, a retrospective study. BMC Neurol. 2010;10:10. Epub 2010 Jan 28. Hikita T, Kodama H, Kaneko S, Amakata K, Ogita K, Mochizuki D, Kaga F, Nakamoto N, Fujii Y, Kikuchi A. Sumatriptan as a treatment for cyclic vomiting syndrome: a clinical trial. Cephalalgia. 2011;31(4):504. Epub 2010 Dec 8. Summarized by Will Dewispelaere, MS3 | Edited by Erik Verzemnieks, MD

 The Free Open Access Medical Education (FOAM) world is often obsessed with magnesium. In this show we address the use of magnesium for various applications. Magnesium for Acute Atrial Fibrillation with Rapid Ventricular Response (RVR) Bouida et al. LOw dose MAGnesium sulfate versus HIgh dose in the early management of rapid atrial fibrillation: randomised controlled double blind study. Acad Emerg Med. 2018 Jul 19. Ho KM, Sheridan DJ, Paterson T. Use of intravenous magnesium to treat acute onset atrial fibrillation: a meta-analysis. Heart. 2007;93(11):1433-40. Davey MJ, Teubner D. A randomized controlled trial of magnesium sulfate, in addition to usual care, for rate control in atrial fibrillation. Ann Emerg Med. 2005;45(4):347-53. Magnesium for Migraine Corbo J, Esses D, Bijur PE, Iannaccone R, Gallagher EJ. Randomized clinical trial of intravenous magnesium sulfate as an adjunctive medication for emergency department treatment of migraine headache. Ann Emerg Med. 2001;38(6):621–7. Bigal ME, Bordini CA, Tepper SJ, Speciali JG. Intravenous magnesium sulphate in the acute treatment of migraine without aura and migraine with aura. A randomized, double-blind, placebo-controlled study. Cephalalgia. 2002;22(5):345-53. 1Cete Y, Dora B, Ertan C, Ozdemir C, Oktay C. A randomized prospective placebo-controlled study of intravenous magnesium sulphate vs. metoclopramide in the management of acute migraine attacks in the Emergency Department. Cephalalgia. 2005;25(3):199–204. Shahrami A, Assarzadegan F, Hatamabadi HR, Asgarzadeh M, Sarehbandi B, Asgarzadeh S. Comparison of therapeutic effects of magnesium sulfate vs. dexamethasone/metoclopramide on alleviating acute migraine headache. J Emerg Med. 2015;48(1):69–76. Orr SL, Friedman BW, Christie S, Minen MT, Bamford C, Kelley NE, et al. Management of Adults with Acute Migraine in the Emergency Department: The American Headache Society Evidence Assessment of Parenteral Pharmacotherapies. Headache. 2016;56(6):911–40. Magnesium for Acute Asthma Exacerbation Griffiths B, Kew KM. Intravenous magnesium sulfate for treating children with acute asthma in the emergency department. Cochrane Database Syst Rev. 2016;4:CD011050. Kew KM, Kirtchuk L, Michell CI. Intravenous magnesium sulfate for treating adults with acute asthma in the emergency department. Cochrane Database Syst Rev. 2014;(5):CD010909.   Thanks for listening! Jeremy Faust and Lauren Westafer

Claire Snyman is an author, blogger and advocate for patient and healthcare collaboration. She is passionate about inspiring people to put their health in their own hands. Since being diagnosed in 2010 with a non-malignant brain tumor and brain surgery in 2012, she realized the importance of partnering with her healthcare team and becoming her body’s own advocate. She co-authored a collaborative study between patients and neurosurgeons at Johns Hopkins University: The impact of surgical resection on headache disability and quality of life in patients with colloid cyst (Cephalalgia, May 10, 2016). She presented this work at MedX-Ed in April 2017: Patient and health care professional collaborations – shaping the future. She recently initiated a new study focused on quality of life in patients with glioblastoma muiltforme, keen to ensure more information is available about this aggressive form of brain cancer. Her key focus is looking for ways to guide people to put their health in their hands and work with their healthcare partners to achieve better outcomes. She currently volunteers with the Brain Tumour Foundation of Canada as the chair of the BrainWAVE BC program. She can be found at www.twosteps.ca.

Mike Rubenstein, from prior episodes on global health and CSF interpretation, returns to discuss the case of a patient with recurrent headaches. But this time he uses big words. Take a listen. Produced by James E. Siegler. Music by Mystery Mammal, Lee Rosevere, Unheard Music Concepts, and Greg Atkinson. Voiceover by Erika Mejia. BrainWaves' podcasts and online content are intended for medical education only and should not be used for routine clinical decision making. REFERENCES Dodick DW. Clinical practice. Chronic daily headache. The New England journal of medicine. 2006;354:158-65. Halker RB, Hastriter EV and Dodick DW. Chronic daily headache: an evidence-based and systematic approach to a challenging problem. Neurology. 2011;76:S37-43. Bigal ME and Lipton RB. The differential diagnosis of chronic daily headaches: an algorithm-based approach. J Headache Pain. 2007;8:263-72. Silberstein SD and Lipton RB. Chronic daily headache. Curr Opin Neurol. 2000;13:277-83. Pareja JA, Antonaci F and Vincent M. The hemicrania continua diagnosis. Cephalalgia. 2001;21:940-6. Prakash S and Patell R. Paroxysmal hemicrania: an update. Curr Pain Headache Rep. 2014;18:407. Goadsby PJ. Trigeminal autonomic cephalalgias. Continuum (Minneap Minn). 2012;18:883-95.

1) Featured Article: Quality improvement in neurology: Child neurology quality measure set2) Lesson of the Week: Update on chronic migraine risk factors, management, and treatmentThis Neurology® Podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the January 9, 2018, issue of Neurology. In the first segment, Dr. Adam Numis talks with Dr. Jeffrey Buchhalter and Dr. Anup Patel about their quality measure set executive summary article regarding child neurology. For the “Lesson of the Week” segment, Dr. Tesha Monteith speaks with Dr. Stephen Silberstein about chronic migraine.DISCLOSURES:Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section; has received speaker honorarium from LivaNova; and has received research support from American Academy of Neurology, Clinical Research Training Fellowship in Epilepsy, 2017-2019, and American Epilepsy Society, Research and Training Fellowships for Clinicians, 2017-2018.Dr. Bucchalter has served on advisory and safety monitoring boards for NIH, NINDS, Observational Safety Monitoring Board for NIH, and the Charlie Foundation; has received travel and speaker honoraria from AAN, Eisai Co. Ltd., Child Neurology Society, Lundbeck, and Upsher-Smith Labs; serves on the editorial board for Pediatric Neurology; has consulted in the past with Lundbeck Inc., Eisai Co. Ltd., UCB, and Upsher-Smith; and has received research support from Alberta Health Services.Dr. Patel has served on scientific advisory board for UCB Pharma; has served as book and associate editor for Journal of Child Neurology; has consulted for Greenwich Biosciences, LivaNova, and Supernus; and has received research support from Greenwich Biosciences, Brain Sentinel, Upsher Smith Pharmaceuticals, LivaNova, Pediatric Epilepsy Research Foundation (PERF), and American Academy of Neurology (AAN).Dr. Silberstein has served on scientific advisory boards for Alder, Allergan, Amgen, Avanir, eNeura, ElectroCore Medical, Medscape, Medtronic, Mitsubishi Tanabe, Neuralieve, NINDS, Pfizer, Supernus, Teva, Curelator, Depomed, Dr. Reddy's Laboratories, Lilly, and Trigemina; has served on editorial boards for Cephalalgia, Current Pain and Headache Reports, CNS Drugs, Topics in Pain Management, and Neurology; has consulted for Allergan, Amgen, eNeura, ElectroCore Medical, Mitsubishi Tanabe, Medtronic, Neuralieve, Pfizer, Supernus, and Teva; served on speaker's bureaus in the past for Allergan, Endo Pharmaceuticals, GlaxoSmithKline, Zogenix, and Merck; and has received research support from GlaxoSmithKline, Allergan, Merck, Novartis, NIH, Neurolieve, MAP, Endo, Amgen, ElectroCore, Avanir, NIH, AHS, and IHS.Dr. Monteith serves as an editorial advisory board member for Neurology Now and receives research support from the NIH.

Show description/summary:1) Medication-overuse headache: An entrenched idea in need of scrutiny 2) What’s Trending: DAWN TrialThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the September 19th, 2017 issue of Neurology. In the first segment, Dr. Alex Menze talks with Dr. Elizabeth Loder about her paper on medication overuse headache. In the second part of the podcast, Dr. Kevin Barrett focuses his interview with Dr. Tudor Jovin on the DAWN trial on Trevo thrombectomy for acute ischemic stroke. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Menze reports no disclosures.Dr. Loder has received travel funding from the American Headache Society and American Migraine Foundation and The British Medical Journal; has served on the editorial boards of The British Medical Journal, Cephalalgia, and Headache; receives publishing royalties from Cambridge University Press; and has received research support from Harvard Medical School.Dr. Barrett serves on the editorial boards of Neurology and Neurohospitalist; receives publishing royalties from Wiley-Blackwell; and has received research support from NINDS.Dr. Jovin has served on the Codman Neurovascular Data Safety Monitoring Board; has received travel funding from Stryker Neurovascular and Fundacio Ictus; and holds stock/stock options in Silk Road Medical, Anaconda, and Blockade Medical.

I recently heard about a medical condition that relates closely to a lot of spiritual teachings. I dug in and found a correlation between a spiritual guru and a condition that he might have suffered during the early years of his life. Find out more in the podcastRamana Maharshi: Barua, A.The silences of Ramana Maharshi: Self-enquiry and liberation in S??khya Yoga and Advaita Ved?nta(2015) Religions of South Asia, 9 (2), pp. 186-207. https://www.scopus.com/inward/record.uri?eid=2-s2.0-84975073388&partnerID=40&md5=ec6bd4bb7df4f20845f9ff5a975fe4afDOI: 10.1558/rosa.v9i2.26921DOCUMENT TYPE: ArticleSOURCE: ScopusLucas, P.C.Non-traditional modern advaita gurus in the west and their traditional modern advaita critics(2014) Nova Religio, 17 (3), pp. 6-37. https://www.scopus.com/inward/record.uri?eid=2-s2.0-84894175588&partnerID=40&md5=430ed78b2d1f8464be60acf485165015DOI: 10.1525/nr.2014.17.3.6DOCUMENT TYPE: ArticleSOURCE: ScopusLucas, P.C.When a movement is not a movement: Ramana Maharshi and Neo-Advaita in North America(2011) Nova Religio, 15 (2), pp. 93-114. Cited 1 time.https://www.scopus.com/inward/record.uri?eid=2-s2.0-84860367975&partnerID=40&md5=bc2462a060296c2d7958404e055f4d74DOI: 10.1525/nr.2011.15.2.93DOCUMENT TYPE: ReviewSOURCE: ScopusStein, R.Snapshots from the Void: Refections on Jung's Relationship to Indian Yoga(2010) Jung Journal: Culture and Psyche, 4 (2), pp. 62-84. https://www.scopus.com/inward/record.uri?eid=2-s2.0-77951815782&partnerID=40&md5=0dc95ee26e1ab14ee2cbb506faaf2259DOI: 10.1525/jung.2010.4.2.62DOCUMENT TYPE: ArticleSOURCE: ScopusForsthoefel, T.A.Weaving the inward thread to awakening: The perennial appeal of Ramana Maharshi(2002) Horizons, 29 (2), pp. 240-259. https://www.scopus.com/inward/record.uri?eid=2-s2.0-70449945473&partnerID=40&md5=bf68b55e1b6cba3ab25cf1c29c014c27Cotards DelusionMeaning: https://en.wikipedia.org/wiki/Cotard_delusionJules Cotard: https://en.wikipedia.org/wiki/Jules_CotardOne of the first documented case reports: KAUBISH, V.K. ON THE DELUSION OF NEGATION AND COTARD'S SYNDROME. [O BREDE OTRITSANIIA I SINDROME KOTARA (1964) Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952), 64, pp. 876-882. Towards Understanding Cotards: http://www.futuremedicine.com/doi/10.2217/npy.12.67Other ReferencesParks, N.E., Rigby, H.B., Gubitz, G.J., Shankar, J.J., Purdy, R.A.Dysmetropsia and Cotard's syndrome due to migrainous infarction - Or not?(2014) Cephalalgia, 34 (9), pp. 717-720. https://www.scopus.com/inward/record.uri?eid=2-s2.0-84904660252&partnerID=40&md5=8f80604f6699faae93e59508b5addc92DOI: 10.1177/0333102414520765DOCUMENT TYPE: ArticleSOURCE: ScopusDebruyne, H., Audenaert, K.Towards understanding Cotards syndrome: An overview(2012) Neuropsychiatry, 2 (6), pp. 481-486. https://www.scopus.com/inward/record.uri?eid=2-s2.0-84871318551&partnerID=40&md5=df65c62a07a840152fa27ee82f4efaecDOI: 10.2217/npy.12.67DOCUMENT TYPE: ArticleSOURCE: ScopusSingh, S.G., Heramani, N., Lenin, R.K., Bihari, Th., Khesoh, N., Debbarma, S.Cotard's syndrome: A case report(2008) JMS - Journal of Medical Society, 22 (3), pp. 153-154. https://www.scopus.com/inward/record.uri?eid=2-s2.0-53849149376&partnerID=40&md5=8f5cc6c7320f340e08ce9132a4a5f1a0DOCUMENT TYPE: ArticleSOURCE: ScopusShiraishi, H., Ito, M., Hayashi, H., Otani, K.Sulpiride treatment of Cotard's syndrome in schizophrenia(2004) Progress in Neuro-Psychopharmacology and Biological Psychiatry, 28 (3), pp. 607-609. Cited 15 times.https://www.scopus.com/inward/record.uri?eid=2-s2.0-1842839790&partnerID=40&md5=d455001cba26ab82c15db8f5d5e9d581DOI: 10.1016/j.pnpbp.2004.01.011DOCUMENT TYPE: ArticleSOURCE: ScopusHagen, S., Voss, S.H.Cotard's syndrome in depression and continuation electroconvulsive therapy (ECT) [Cotards syndrom ved depression og vedligeholdelsesbehandling med elektrokonvulsiv terapi](2002) Ugeskrift for Laeger, 164 (26), pp. 3452-3453. Cited 6 times.https://www.scopus.com/inward/record.uri?eid=2-s2.0-0037166502&partnerID=40&md5=6ab35665a9a1a736af126a4f05cee165DOCUMENT TYPE: ArticleSOURCE: ScopusMalone, K.Remarkable resolution of an uncommon psychosyndrome: Epilepsy-induced remission of Cotard's syndrome(1992) Irish Journal of Psychological Medicine, 9 (1), pp. 53-54. Cited 2 times.https://www.scopus.com/inward/record.uri?eid=2-s2.0-0026703893&partnerID=40&md5=003b6df0346f0db1c857276446aea84bDOI: 10.1017/S0790966700013963DOCUMENT TYPE: ArticleSOURCE: ScopusMatsukura, S., Yoshimi, H., Sueoka, S., Chihara, K., Fujita, T., Tanimoto, K.?-ENDORPHIN IN COTARD'S SYNDROME(1981) The Lancet, 317 (8212), pp. 162-163. Cited 4 times.https://www.scopus.com/inward/record.uri?eid=2-s2.0-0019883112&partnerID=40&md5=c8ee927c972c945f06f536b092485772DOI: 10.1016/S0140-6736(81)90758-3DOCUMENT TYPE: LetterSOURCE: ScopusKAUBISH, V.K.ON THE DELUSION OF NEGATION AND COTARD'S SYNDROME. [O BREDE OTRITSANIIA I SINDROME KOTARA(1964) Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952), 64, pp. 876-882. https://www.scopus.com/inward/record.uri?eid=2-s2.0-76549162680&partnerID=40&md5=72448e80e5dcd36740354617f1833acd

I recently heard about a medical condition that relates closely to a lot of spiritual teachings. I dug in and found a correlation between a spiritual guru and a condition that he might have suffered during the early years of his life. Find out more in the podcastRamana Maharshi: Barua, A.The silences of Ramana Maharshi: Self-enquiry and liberation in S??khya Yoga and Advaita Ved?nta(2015) Religions of South Asia, 9 (2), pp. 186-207. https://www.scopus.com/inward/record.uri?eid=2-s2.0-84975073388&partnerID=40&md5=ec6bd4bb7df4f20845f9ff5a975fe4afDOI: 10.1558/rosa.v9i2.26921DOCUMENT TYPE: ArticleSOURCE: ScopusLucas, P.C.Non-traditional modern advaita gurus in the west and their traditional modern advaita critics(2014) Nova Religio, 17 (3), pp. 6-37. https://www.scopus.com/inward/record.uri?eid=2-s2.0-84894175588&partnerID=40&md5=430ed78b2d1f8464be60acf485165015DOI: 10.1525/nr.2014.17.3.6DOCUMENT TYPE: ArticleSOURCE: ScopusLucas, P.C.When a movement is not a movement: Ramana Maharshi and Neo-Advaita in North America(2011) Nova Religio, 15 (2), pp. 93-114. Cited 1 time.https://www.scopus.com/inward/record.uri?eid=2-s2.0-84860367975&partnerID=40&md5=bc2462a060296c2d7958404e055f4d74DOI: 10.1525/nr.2011.15.2.93DOCUMENT TYPE: ReviewSOURCE: ScopusStein, R.Snapshots from the Void: Refections on Jung's Relationship to Indian Yoga(2010) Jung Journal: Culture and Psyche, 4 (2), pp. 62-84. https://www.scopus.com/inward/record.uri?eid=2-s2.0-77951815782&partnerID=40&md5=0dc95ee26e1ab14ee2cbb506faaf2259DOI: 10.1525/jung.2010.4.2.62DOCUMENT TYPE: ArticleSOURCE: ScopusForsthoefel, T.A.Weaving the inward thread to awakening: The perennial appeal of Ramana Maharshi(2002) Horizons, 29 (2), pp. 240-259. https://www.scopus.com/inward/record.uri?eid=2-s2.0-70449945473&partnerID=40&md5=bf68b55e1b6cba3ab25cf1c29c014c27Cotards DelusionMeaning: https://en.wikipedia.org/wiki/Cotard_delusionJules Cotard: https://en.wikipedia.org/wiki/Jules_CotardOne of the first documented case reports: KAUBISH, V.K. ON THE DELUSION OF NEGATION AND COTARD'S SYNDROME. [O BREDE OTRITSANIIA I SINDROME KOTARA.] (1964) Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952), 64, pp. 876-882. Towards Understanding Cotards: http://www.futuremedicine.com/doi/10.2217/npy.12.67Other ReferencesParks, N.E., Rigby, H.B., Gubitz, G.J., Shankar, J.J., Purdy, R.A.Dysmetropsia and Cotard's syndrome due to migrainous infarction - Or not?(2014) Cephalalgia, 34 (9), pp. 717-720. https://www.scopus.com/inward/record.uri?eid=2-s2.0-84904660252&partnerID=40&md5=8f80604f6699faae93e59508b5addc92DOI: 10.1177/0333102414520765DOCUMENT TYPE: ArticleSOURCE: ScopusDebruyne, H., Audenaert, K.Towards understanding Cotards syndrome: An overview(2012) Neuropsychiatry, 2 (6), pp. 481-486. https://www.scopus.com/inward/record.uri?eid=2-s2.0-84871318551&partnerID=40&md5=df65c62a07a840152fa27ee82f4efaecDOI: 10.2217/npy.12.67DOCUMENT TYPE: ArticleSOURCE: ScopusSingh, S.G., Heramani, N., Lenin, R.K., Bihari, Th., Khesoh, N., Debbarma, S.Cotard's syndrome: A case report(2008) JMS - Journal of Medical Society, 22 (3), pp. 153-154. https://www.scopus.com/inward/record.uri?eid=2-s2.0-53849149376&partnerID=40&md5=8f5cc6c7320f340e08ce9132a4a5f1a0DOCUMENT TYPE: ArticleSOURCE: ScopusShiraishi, H., Ito, M., Hayashi, H., Otani, K.Sulpiride treatment of Cotard's syndrome in schizophrenia(2004) Progress in Neuro-Psychopharmacology and Biological Psychiatry, 28 (3), pp. 607-609. Cited 15 times.https://www.scopus.com/inward/record.uri?eid=2-s2.0-1842839790&partnerID=40&md5=d455001cba26ab82c15db8f5d5e9d581DOI: 10.1016/j.pnpbp.2004.01.011DOCUMENT TYPE: ArticleSOURCE: ScopusHagen, S., Voss, S.H.Cotard's syndrome in depression and continuation electroconvulsive therapy (ECT) [Cotards syndrom ved depression og vedligeholdelsesbehandling med elektrokonvulsiv terapi](2002) Ugeskrift for Laeger, 164 (26), pp. 3452-3453. Cited 6 times.https://www.scopus.com/inward/record.uri?eid=2-s2.0-0037166502&partnerID=40&md5=6ab35665a9a1a736af126a4f05cee165DOCUMENT TYPE: ArticleSOURCE: ScopusMalone, K.Remarkable resolution of an uncommon psychosyndrome: Epilepsy-induced remission of Cotard's syndrome(1992) Irish Journal of Psychological Medicine, 9 (1), pp. 53-54. Cited 2 times.https://www.scopus.com/inward/record.uri?eid=2-s2.0-0026703893&partnerID=40&md5=003b6df0346f0db1c857276446aea84bDOI: 10.1017/S0790966700013963DOCUMENT TYPE: ArticleSOURCE: ScopusMatsukura, S., Yoshimi, H., Sueoka, S., Chihara, K., Fujita, T., Tanimoto, K.?-ENDORPHIN IN COTARD'S SYNDROME(1981) The Lancet, 317 (8212), pp. 162-163. Cited 4 times.https://www.scopus.com/inward/record.uri?eid=2-s2.0-0019883112&partnerID=40&md5=c8ee927c972c945f06f536b092485772DOI: 10.1016/S0140-6736(81)90758-3DOCUMENT TYPE: LetterSOURCE: ScopusKAUBISH, V.K.ON THE DELUSION OF NEGATION AND COTARD'S SYNDROME. [O BREDE OTRITSANIIA I SINDROME KOTARA.](1964) Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952), 64, pp. 876-882. https://www.scopus.com/inward/record.uri?eid=2-s2.0-76549162680&partnerID=40&md5=72448e80e5dcd36740354617f1833acd

1) The association between hospitalization and care after transient ischemic attack or minor stroke2) e-Pearl topic: Neuroretinitis3) Topic of the month: Migraine awareness seriesThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Southerland interviews Dr. Moira Kapral about her paper on the association between hospitalization and care after transient ischemic attack or minor stroke. Dr. Sarah Wesley is reading our e-Pearl of the week about neuroretinitis. Dr. Tesha Monteith interviews Dr. Stephen Silberstein about the topic of migraine clinical trials: A drug therapy and neuromodulation update. DISCLOSURES: Dr. Southerland serves as Podcast Deputy Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: “Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke viamobile telemedicine;” and gave legal expert review.Dr. Kapral serves as Guest Editor for Cardiovascular Quality and Outcomes; serves as an editorial board member of Circulation; receives research support from the Heart and Stroke Foundation of Canada.Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section.Dr. Monteith serves as an editorial advisory board member for Neurology Now and receives research support from the NIH.Dr. Silberstein serves as an editorial board member of Cephalalgia, Current Pain and Headache Reports, CNS Drugs, Topics in Pain Management and Neurology®; serves on the scientific advisory board for Alder, Allergan, Inc., Amgen, Avanir, eNeura, ElectroCore Medical, Medscape, Medtronic, Inc., Mitsubishi Tanabe Pharma Corporation, Neuralieve, NINDS, Pfizer Inc, Supernus and Teva Pharmaceutical Industries Ltd.; is a consultant for Allergan, Inc., Amgen, eNeura, ElectroCore Medical, Mitsubishi Tanabe, Medtronic, Inc., Neuralieve, Pfizer, Inc, Supernus and Teva Pharmaceutical Industries Ltd.; receives research support from American Headache Society®, International Headache Society and the NIH.

  Dr David Dodick interviews Dr Rami Burstein about his paper in Cephalalgia - Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: Therapeutic implications for migraine and other pains.   Read the associated full research article here.  

1) Migraine and structural changes in the brain and 2) Topic of the month: Multiple sclerosis therapy and treatment. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jennifer Bickel interviews Dr. Messoud Ashina about his paper on migraine and structural changes in the brain. Dr. Adam Numis is reading our e-Pearl of the week about manganese neurotoxicity. In the next part of the podcast Dr. Mark Keegan interviews Dr. Paul O' Connor about teriflunomide for the treatment of multiple sclerosis. The participants had nothing to disclose except Drs. Ashima, Numis, Keegan, and O'Connor.Dr. Ashina serves as an Associate Editor of Cephalalgia; serves on the scientific advisory board for The Journal of Headache and Pain; is a consultant for ATI, Allergan, Inc., Amgen and Alder Biopharmaceuticals, Inc.; received honoraria for lecturing from Allergan Inc.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Keegan serves as Chief Editor of eMedicine and receives research support from Terumo BCT.Dr. O'Connor serves on the scientific advisory boards of Novartis Fingolimod Steering Committee, Sanofi-aventis Teriflunomide Steering Committee, BRAVO (laquinimod) study DMC-chairman, Genetech, Inc. Roche, Acetelion Pharmaceuticals Ltd, Receptos, Inc; received honoraria for attending two Advisory board meetings; served on the editorial advisory board for the MS Journal; serves as a consultant for Biogen Idec, Merck Serono, is currently a consultant for Teva Pharmaceutical Industries Ltd., Sanofi-aventis, Novartis; receives research support from Novartis, Sanofi-aventis, Roche, Biogen Idec, and from the MS Society of Canada as National Scientific and Clinical Advisor.

Dr Borsook presents a lecture on the Cephalalgia Award winning paper - Concurrent functional and structural cortical alterations in migraine

Dr David Dodick and Professor Arne May discuss the pearls and pitfalls in headache research following the release of the June 2013 special issue

1) Evidence-based guideline updates on episodic migraine prevention and 2) Topic of the month: Obesity and the neurology patient. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Drs. Stephen D. Silberstein and Starr Holland on the guideline updates about treatments for episodic migraine prevention in adults. Dr. Chafic Karam is reading our e-Pearl of the week about scapular winging. In the next part of the podcast Dr. Ted Burns interviews Dr. Lisa Davis about her recent paper titled: Clinical strategies for managing the overweight neurology patient published in the March Neurology Clinical Practice Journal. All participants have disclosures.Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Silberstein serves on scientific advisory boards for AGA Medical Corporation, Allergan, Inc., Amgen, CAPNIA, Coherex Medical, GlaxoSmithKline, Iroko Pharmaceuticals, LLC, Eli Lilly and Company, MAP Pharmaceuticals, Inc., Medtronic, Inc., Merck Serono, Neuralieve Inc., the NIH/NINDS, NuPathe Inc., Pfizer Inc, and St. Jude Medical; serves on the editorial boards of Cephalalgia and Current Pain and Headache Reports; serves on the speakers' bureaus for Allergan, Inc., Endo Pharmaceuticals, GlaxoSmithKline, Zogenix, and Merck Serono; serves as a consultant for Amgen, Nautilus, Inc., Novartis, Opti-Nose, and Zogenix; receives publishing royalties for Wolff's Headache, 8th edition (Oxford University Press, 2009) and Handbook of Headache (Cambridge University Press, 2010); his employer receives research support from Allergan, Endo, GlaxoSmithKline, MAP, Merck Serono, the NIH/NINDS, Novartis, and Neurolieve; receives research support from the American Headache Society and the International Headache Society.Dr. Holland serves as a consultant for MAP Pharmaceuticals, Inc.; receives research support from Albert Einstein College of Medicine and the American Headache Society.Dr. Karam serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Davis serves as a consultant for Medifast, Inc. and the Coleman Research Group and is a shareholder in Medifast, Inc.

Dr Arne May presents a lecture on the Cephalalgia Award winning paper - A new trigemino-nociceptive stimulation model for event-related fMRI.